| 1/21 | US=9 / Urologia Rosenberg J. Beyond Docetaxel: emerging agents in the treatment of advanced prostate cancer. In: Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer - Verlag, 2010. p. 147-51. ISBN 978-1-60327-831-7. DOCETAXEL; CANCER DE PROSTATA AVANCADO; INIBICAO DE MTOR; NOVAS TERAPEUTICAS; DESACETILACAO DAS HISTONAS; HSP90; FATOR 1 DE CRESCIMENTO COM INSULINA |
| 2/21 | US=24 / Câncer Milne TA, Zhao K, HJess JL. Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins. In: Eric So CW, editor. Leukemia: methods and protocols. New York: Humana Press, 2009. p. 409-23. ISBN 978-1-58829-989-5. CROMATINA IMUNOPRECIPITACAO; CHIP; MODIFICACAO DAS HISTONAS; ACETILACAO; METILACAO; PCR QUANTITATIVO; SAGE |
| 3/21 | US=101 / Câncer Glauben R, Siegmund B. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer. In: Kozlov SV, editor. Inflammation and cancer: methods and protocols. volume 2, molecular analysis and pathways. New York: Humana Press, 2009. p. 365-76. (Methods in Molecular Biology, 512) ISBN 978-1-60327-529-3. HISTONAS; ACETILACAO; INFLAMACAO; EPIGENETICA; CELULAS T HELPER; APOPTOSE |
| 4/21 | US=49-F / Câncer Kampranis SC, Tsichlis PN. Histone demethylases and cancer. In: Woude GFV, Klein G. Advances in cancer research. Amsterdam: Elsevier, 2009. p. 103-69. ISBN 978-0-12-3744371. DEMETILASE HISTONAS E CANCER; ENZIMAS; DEMETILASE HISTONAS E CANCER. TERAPIA TARDIA |
| 5/21 | US=47 / Câncer Gabrielli B, Stevens F, Beamish H. Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 291-309. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DAS HISTONAS DESACETILASES; CONTROLE DO CICLO CELULAR; HETEROCROMATINA; LETALIDADE SINTETICA; PASSAGEIROS CROMOSSOMICOS |
| 6/21 | US=67 / Biol/Mol Thiagalingam S, Faller DV. The cancer epigenome: cann it be targeted for therapy?. In: Kaufman HL, Wadler S, Antman K. Molecular targeting in oncology. New Jersey: Humana Press, 2008. p. 97-113. (Cancer Drug Discovery and Development) ISBN 978-1-58829-577-4. CANCER; EPIGENOMA; METILACAO DO DNA; DNA METIL TRANSFERASE; HISTONA ACETILTRANSFERASE; HISTONA-DESACETILASE; CODIGO DE HISTONAS; CODIGO EPIGENOMICO ATIVA; CODIGO EPIGENOMICO SILENCIADO; INIBIDOR DE HISTONA-DESACETILASE; TERAPIA DO CANCER |
| 7/21 | US=84-A / Biol/Mol Ammanamanchi S, Brattain MG. Transformig growth factor-B in developing and advanced cancers: DNA methylation and histone deacetylation inhibitors as potential therapeutic agents for the reconstitution of TGF-B signaling in breast cancer. In: Jakowlew SB. Transforming growth factor-beta in cancer therapy: cancer treatment and therapy. Amsterdam: Elsevier, 2008. p. 463-74. (Cancer Drug Discovery and Development) ISBN 978-1-58829-715-0. METILACAO DO DNA; DECITABINA; DESACETILACAO DAS HISTONAS; RII; TGF-B RECEPTOR TIPO II; SP FAMILIA DE GENES; TRICOSTATINA A |
| 8/21 | US=111 / Câncer Ballestar E, Esteller M. The role of epigenetic in cancer. In: Alison MR. The cancer handbook. 2nd ed. New Jersey: John Wiley & Sons, 2007. p. 70-5. ISBN 978-0-470-01852-1. CANCER; EPIGENETICA; HIPERMETILACAO DO DNA; HIPOMETILACAO DO DNA; MODIFICACAO DE HISTONAS; MUDANCAS EPIGENETICAS ESPECIFICAS; MUDANCAS EPIGENETICAS ALEATORIAS; TERAPIA EPIGENETICA |
| 9/21 | US=16 / Urologia Kortenhorst MSQ, Carducci MA, Shabbeer S. Therapeutics: differentiation agents and epigenomic therapies. In: Chung LWK, Isaacs WB, Simons JW. Prostate cancer: biology, genetics, and the new therapeutics. 2ª ed. New Jersey: Humana Press, 2007. p. 411-43. (Contemporary Cancer Research) ISBN 978-1-58829-696-2. CANCER DE PROSTATA; TERAPEUTICA; AGENTES DE DIFERENCIACAO; TERAPIA EPIGENOMICA; ACETILACAO; MODIFICACAO DA CROMATINA; REMODELAMENTO DA CROMATINA; ENSAIOS CLINICOS; EPIGENETICA; HISTONA ACETIL TRANSFERASE; CODIGO DE HISTONAS; INIBIDOR DE HISTONA-DESACETILASE; METILACAO; INIBIDOR METIL TRANSFERASE |
| 10/21 | US=46 / Câncer Bunger MK, Archer TK. Epigenetic mechanisms in tumorigenesis. In: Meyers RA. Cancer: from mechanisms to therapeutic approaches. New Jersey: Wiley-Blackwell, 2007. p. 115-53. ISBN 978-3-527-31768-4. MECANISMOS EPIGENETICOS NA CARCINOGENESE; EPIGENETICA; HISTONAS; NUCLEOSOME; CROMATINA; HETEROCROMATINA; PERDA DE HETEROZIGOSE |
| 11/21 | US=68 / Biol/Mol Dasgupta P, Chellappan SP. Chromatin immunoprecipitation assays. In: Fisher PB. Cancer genomics and proteomics: methods and protocols. New Jersey: Humana Press, 2007. p. 135-52. (Methods in Molecular Biology, 383) ISBN 978-1-58829-504-0. ENSAIOS DE IMUNOPRECIPITACAO DE CROMATINA; ACETILACAO; CHIP; E2F; MODIFICACAO DAS HISTONAS; IMUNOPRECIPITACAO; MICROARRAYS |
| 12/21 | US=88 / Biol/Mol Saldanha SN, Tollefsbol TO. Alterations in histone acetylation in tumorigenesis. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 97-108. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; TUMORIGENESE; ACETILACAO DAS HISTONAS; NUCLEOSSOMOS |
| 13/21 | US=88 / Biol/Mol Hung S. Histone methylation and the initation of cancer. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 109-50. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; METILACAO DE HISTONAS; HERANCA EPIGENETICA; METILTRANSFERASES DE HISTONAS; METILACAO DO DNA |
| 14/21 | US=88 / Biol/Mol Zhang X, Hsieh TI, Nicosia SV, Bai W. Role of sirtuins in aging and tumorigenesis. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 151-80. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; TUMORIGENESE; SIRTUINAS; ENVELHECIMENTO; HISTONAS DEACETYLASES |
| 15/21 | US=88 / Biol/Mol Ao A, Lu J. Proteins that alter histone modifications in cancer. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 181-95. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; PROTEINAS; HISTONAS; ACETILTRANSFERASE; DEACETILASE; METILTRANSFERASE |
| 16/21 | US=88 / Biol/Mol Verma M, Kumar D. Diagnosing cancer using histone modification analysis. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 347-57. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; CANCER. DIAGNOSTICO; ANALISE DE MODIFICACAO DAS HISTONAS |
| 17/21 | US=88 / Biol/Mol McBrian MA, Seligson DB, Kurdistani SK. Histone modifications in cancer biology and prognosis. In: Tollefsbol T. Cancer epigenetics. Boca Raton: CRC, 2009. p. 359-79. ISBN 978-1-4200-4579-6. CANCER; EPIGENETICA; CANCER. PROGNOSTICO; MODIFICACOES DAS HISTONAS; ACETILACAO DA HISTONA; METILACAO DA HISTONA |
| 18/21 | US=61 / Câncer Teodoridis JM, Brown R. Biochemical resistance: CpG island methylation and drug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 359-75. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1. |
| 19/21 | US=62 / Biol/Mol Futscher BW, Domann FE. Epigenetic regulation of genes that affect tumor cell adhesion. In: Cress AE, Nagle RB. Cell adhesion and cytoskeletal molecules in metastasis. New York: Springer, 2006. p. 123-40. (Cancer Metastasis - Biology and Treatment, 9) ISBN 978-1-4020-5128-9. REGULACAO EPIGENETICA DE GENES; ADESAO DE CELULAS TUMORAIS; MASPIN; CANCER EPITELIAL; ILHAS CPG; METILACAO DO DNA; DESACETILACAO DAS HISTONAS; CANCER DE MAMA; CANCER DE PROSTATA; MARCADORES EPIGENETICOS |
| 20/21 | US=120 / Câncer Viola JPB, Mognol GP. Fatores de transcrição e regulação da expressão gênica. In: Hoff PMG. Tratado de oncologia. São Paulo: Atheneu, 2013. p. 217-229. ISBN 85-388-0312-6. REGULACAO GERAL DA TRANSCRICAO EM EUCARIOTOS; GENES SUPRESSORES DE TUMOR. FATORES DE TRANSCRICAO; ONCOGENES. FATORES DE TRANSCRICAO; MODIFICACOES DA CROMATINA E SEUS MECANISMOS DE ACAO; METILACAO DE SITIOS CPG; MODIFICACOES DE HISTONAS; MOVIMENTO DE NUCLEOSSOMOS; MIRNAS; MODIFICACOES DE CROMATINA E MIRNAS NO CANCER |